GSK.L - GlaxoSmithKline plc
| Previous Close | 1,443.00 |
| Open | 1,469.80 |
| Bid | 1,471.20 x 0 |
| Ask | 1,471.80 x 0 |
| Day's Range | 1,415.80 - 1,481.40 |
| 52 Week Range | 1,328.19 - 1,857.00 |
| Volume | 4,685,570 |
| Avg. Volume | 12,486,555 |
| Market Cap | 73.841B |
| Beta (5Y Monthly) | 0.46 |
| PE Ratio (TTM) | 15.89 |
| EPS (TTM) | 92.60 |
| Earnings Date | Apr 29, 2020 |
| Forward Dividend & Yield | 0.92 (6.13%) |
| Ex-Dividend Date | Feb 20, 2020 |
| 1y Target Est | 1,644.50 |
- Yahoo Finance
Health officials: No evidence Ibuprofen is dangerous to coronavirus patients
Health officials say there is no scientific evidence that ibuprofen is harmful for COVID-19 patients.
- MarketWatch
These 16 companies are working on coronavirus treatments or vaccines — here’s where things stand
A mix of legacy drugmakers and small startups have stepped forward with plans to develop vaccines or treatments that target the infection caused by the novel coronavirus.
- GuruFocus.com
3 Digital Health Care Stocks to Consider as Doctors Move Online
Covid-19 has more doctors going digital to maximize time and safety for medical workers Continue reading...
- MarketWatch
Dynavax's stock rises 10% on expanded CEPI partnership
Shares of Dynavax Technologies Corp. gained 10% in trading on Thursday after the company said it's making its adjuvant technology available to companies developing COVID-19 vaccines through a partnership with the Coalition for Epidemic Preparedness Innovations (CEPI), a not-for-profit organization in Oslo that has provided funding to a handful of vaccine developers in this pandemic. Dynavax's adjuvant technology can help provide an increased immune response to a vaccine; the biopharmaceutical company is also working with the University of Queensland, Australia, on vaccine development through a CEPI deal. GlaxoSmithKline , which is lending its adjuvant technology to COVID-19 vaccine development plans, has also partnered with CEPI, the University of Queensland, and Clover Biopharmaceuticals Inc., a Chinese biotechnology company, the same as Dynavax. Dynavax's stock is down 42% year-to-date. The S&P 500 has dropped 23%.
- Investor's Business Daily
Pfizer Is Entering The Coronavirus Drug Hunt — But Is PFE Stock A Buy?
Pfizer stock is on a recent downswing in the wake of lackluster fourth-quarter earnings, though the company is partnering on a coronavirus vaccine. Is the pharma company a buy right now?
- Zacks
Lilly Halts Enrollment, Biotechs Focus to Find Coronavirus Cure
Supply-chain disruptions due to coronavirus outbreak may hurt biotech companies' first-quarter earnings. However, those making treatments/vaccines may make huge profits if their products get approval.
- Zacks
Glaxo's Long-Acting HIV Regimen Cabenuva Gets Canada's Nod
Glaxo's (GSK) long-acting injectable regimen of cabotegravir and rilpivirine gets its first approval for the treatment of HIV-1 infection in virologically-suppressed adults
- MarketWatch
Does ibuprofen make the coronavirus worse? Is it still safe to take aspirin?
This has been another tough pill to swallow: France’s health ministry has suggested that certain painkillers could aggravate the effects of the coronavirus. Olivier Veran tweeted last week that some nonsteroidal anti-inflammatories (aka NSAIDs) worsen the effects of COVID-19, the disease caused by the novel coronavirus. If you have a fever, take paracetamol [aka acetaminophen].
- Investor's Business Daily
Stocks Showing Improved Relative Strength: Glaxosmithkline
A Relative Strength Rating upgrade for Glaxosmithkline shows improving technical performance. Will it continue?
- Zacks
The Zacks Analyst Blog Highlights: ORCL, CSCO, NFLX, GSK and CCI
The Zacks Analyst Blog Highlights: ORCL, CSCO, NFLX, GSK and CCI
- MarketWatch
Here’s one analyst’s take on the coronavirus drugs for today and the future
Analysts at Bernstein Research in a comprehensive note discussed what approaches are worth keeping an eye on.
- Zacks
These 10 Drug Companies are Testing a Coronavirus Vaccine
As the coronavirus pandemic continues to spread, some of the biggest drug companies are moving closer to finding a vaccine.
- Zacks
Top Research Reports for Oracle, Cisco & Netflix
Top Research Reports for Oracle, Cisco & Netflix
- Simply Wall St.
Does GlaxoSmithKline plc's (LON:GSK) CEO Salary Reflect Performance?
Emma Walmsley has been the CEO of GlaxoSmithKline plc (LON:GSK) since 2017. This report will, first, examine the CEO...
- Insider Monkey
Here is What Hedge Funds Think About GlaxoSmithKline plc (GSK)
Coronavirus is probably the 1 concern in investors' minds right now. It should be. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW. We predicted that a US recession is imminent and US stocks will go down by at least 20% in the next 3-6 […]
- Thomson Reuters StreetEvents
Edited Transcript of GSK.L earnings conference call or presentation 5-Feb-20 2:00pm GMT
Q4 2019 GlaxoSmithKline PLC Earnings Call
- Zacks
AbbVie Backs Studies on HIV Drug Kaletra for Coronavirus Cure
AbbVie (ABBV) donates Kaletra/Aluvia to the government of China for experimental use in coronavirus treatment
- Benzinga
How Close Are Biotechs To Bringing A COVID-19 Treatment To Market?
The COVID-19 virus has sent the market and the global economy into a tailspin. The Organisation for Economic Co-operation and Development slashed its global growth forecast for 2020 Monday by 0.5 points to 2.5% versus already-weak 2.9% growth in 2019.Global banks have begun talking up the economy with the promise of stimulus injection.As the world and China in particular battle the deadly pandemic, a small batch of biotechs and a handful of big pharma companies are racing against time to bring to the market potential treatment and/or vaccines to combat the virus.Rocky R&D Pathway For Coronavirus Products Investors scurrying for cover amid the bloodbath in the stock market are investing in biotechs that are targeting the new coronavirus.COVID-19 levered biotechs are offering investors an opportunity due to the kind of returns the stocks can generate in the eventuality that R&D efforts come to fruition.Given that most of the investigational therapies are vaccines are only in the animal testing stage, is it too early to take a headlong plunge into these stocks?"Given the community spread in the U.S., particularly in the states of Washington and California, we believe the current administration's support for rapid development of vaccines and therapies in the U.S. could pave the way for an accelerated regulatory pathway to be made available by government agencies for the rapid market entry of such products that show conclusive efficacy against COVID-19," H.C. Wainwright analyst Raghuram Selvaraju said in a note.The analyst estimates it would take around 18-24 months to complete the clinical development of a COVID-19 vaccine.Benzinga reviewed the COVID-19-related updates from biotechs to gain an understanding of how close each is in bringing a treatment or vaccine to market. See Also: Attention Biotech Investors: Mark Your Calendar For These March PDUFA DatesGilead: The Frontrunner? Large-cap biopharma Gilead Sciences, Inc.'s (NASDAQ: GILD) investigational drug remdesivir has the World Health Organization's seal of approval."There is only one drug right now that we think may have real efficacy and that's remdesivir," WHO assistant director-general Bruce Aylward said at a late February press briefing in China.Remdesivir is an investigational nucleotide analog with broad spectrum antiviral activity that has shown in vitro and in vivo activity in animal models against the viral pathogens MERS and SARS.Gilead has initiated two Phase 3 studies in adults diagnosed with COVID-19 following the FDA's rapid review and acceptance of the IND filed by the company.The company said it expects to enroll 1,000 patients at medical centers, mainly in Asia, beginning in March.Chinese health authorities have initiated two trials with remdesivir in infected patients in the Hubei province, and those clinical trial results are anticipated in April.The U.S. National Institute of Allergy and Infectious Diseases, or NIAID, has initiated a Phase 2 study to test remdesivir in hospitalized adult patients diagnosed with COVID-19.Inovio Sets Timeline Inovio Pharmaceuticals Inc (NASDAQ: INO) is working with Chinese contract development manufacturer Beijing Advaccine Biotechnology to develop INO-4800, a DNA vaccine for COVID-19, unveiled an accelerated development timeline.The company expects to commence a Phase 1 trial in April and mass produce the vaccine by the end of 2020 to be used in case of emergency or for further trials.One advantage of DNA vaccines is that they do not require refrigeration or cold chain logistics, according to H.C. Wainwright. Moderna's Vaccine Candidate To Enter Clinics Moderna Inc (NASDAQ: MRNA) said in late February it has shipped MRNA-1273, its mRNA vaccine targeting COVID-19, to the NIAID to be used in a Phase 1 study.H.C. Wainwright said Moderna could begin Phase 1 trials around the same time as Inovio.Novavax In Animal Testing Novavax, Inc. (NASDAQ: NVAX) said in late February that it is assessing multiple nanoparticle vaccine candidates in animal models to zero in on an optimal candidate for human testing.The company said it expects clinical trials to begin by the end of spring 2020. Vir Biotech Identifies Antivirals Vir Biotechnology Inc (NASDAQ: VIR) is working with WuXi Biologics on a COVID-19 treatment. The company said it has identified a number of monoclonal antibodies that bind to COVID-19 and is conducting research to determine if these can be effective as treatment and/or prophylaxis against the virus.Cocrystal Pharma Licenses Treatment Candidates Cocrystal Pharma Inc (NASDAQ: COCP) said Feb. 24 it has licensed from the Kansas State University Research Foundation antiviral compounds to treat norovirus and coronavirus infections. The company said it plans to pursue preclinical and clinical development of these compounds.NanoViricides Screens Compounds NanoViricides Inc (NYSE: NNVC) said in its fourth-quarter earnings release Feb. 24 it intends to perform initial testing of drug candidates for safety and effectiveness in cell culture studies in its own BSL-2 virology laboratory at its Shelton campus, using low-threat coronavirus strains.Vaxart's Vaccine Program Kicks Off Vaxart Inc (NASDAQ: VXRT) said in late January it has begun work on a program to develop an oral COVID-19 vaccine.The company said it plans to generate vaccine candidates based on the published genome of the coronavirus. Glaxo Lends Tech To Enhance Vaccine Efficiency GlaxoSmithKline plc (NYSE: GSK), though not developing a vaccine, has forged two tie-ups to aid COVID-19 vaccine research.The company announced a collaboration with the Coalition of Epidemic Preparedness Innovations, or CEPI, to provide its pandemic vaccine adjuvant vaccine technology to enhance the development of an effective vaccine against COVID-19.An adjuvant is added to vaccines to enhance its immune response. CEPI will work with Glaxo and entities funded by it that want to test their vaccine platform with Glaxo's adjuvant technology.Glaxo also announced Feb. 24 a research collaboration with Chinese biotech Clover for the latter's protein-based COVID-19 vaccine candidate S-Trimer, which is to be tested with the former's pandemic adjuvant system in preclinical studies.J&J, Sanofi Work With BARDA Johnson & Johnson (NYSE: JNJ) said in mid-February that its Janssen unit will work along with the Biomedical Advanced Research and Development Authority, or BARDA, on potential treatments for COVID-19.Janssen will work with the Belgium-based Rega Institute for Medical Research for screening potential compounds.The company said it is working with BARDA on a COVID-19 vaccine that will leverage its AdVac and PER.C6 technologies, which the company said will help rapidly upscale production of an optimal vaccine candidate.Sanofi SA (NASDAQ: SNY) also has a working relationship with BARDA to develop a COVID-19 vaccine using its recombinant DNA platform that it said will help produce an exact genetic match to proteins or antigenfound on the surface of the virus.This could be formulated to stimulate an immune response to protect against the virus, Sanofi said. Pfizer Joins The Race Pfizer Inc. (NYSE: PFE) reportedly said Monday it has identified some antiviral compounds from its development pipeline that could potentially treat COVID-19 infection.The pharma company said it plans to work with a third party to screen the compounds, with the results from the screening expected by the end of March. If they are found effective, Pfizer said it plans to begin clinical trials by the end of the year.The Race For COVID-19 Drugs Gilead as well as Moderna and Inovio could have an edge over the others, as Gilead's remdesivir is already in the clinics, while the latter two are set to start Phase 1 trials soon.Most others are still screening compounds or pursuing animal testing.The sell-side is guarded in its view regarding the value a potential therapy/vaccine could bring to its developer."Previous potential therapeutics for pandemics have failed to generate value in the medium-to-long term," Baird analyst Madhu Kumar said in a recent note.Photo courtesy of the CDC. Latest Ratings for GILD DateFirmActionFromTo Mar 2020RBC CapitalDowngradesTop PickOutperform Feb 2020DZ BankDowngradesBuyHold Feb 2020BarclaysInitiates Coverage OnUnderweight View More Analyst Ratings for GILD View the Latest Analyst Ratings See more from Benzinga * The Daily Biotech Pulse: Mesoblast To Test Candidate On Coronavirus Symptoms, Proxy Battle Ahead For Rockwell Medical, Glaukos to Join S&P SmallCap 600 Index * The Week Ahead In Biotech (March 8-14): Bristol-Myers Awaits FDA Nod For Liver Cancer Combo Therapy, Earnings Flow Continues * 4 Biotech Stocks Moving On COVID-19 Updates(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
- American City Business Journals
Why GSK's ViiV is doubling down on a $20 million partnership with UNC
A public-private partnership between ViiV Healthcare and UNC-Chapel Hill has been renewed – bringing another $20 million to Triangle researchers working to discover a cure for HIV.
- Reuters
GSK's HIV combo treatment meets main goal in late-stage study
GlaxoSmithKline PLC's unit ViiV Healthcare said on Monday its two-drug regimen to treat HIV was as effective in patients given the treatment every two months, as when administered once a month. The drug, Cabenuva, the long-acting injectable two-drug regimen of antiviral compounds cabotegravir and Johnson & Johnson's rilpivirine, met the main goal at the end of 48 weeks. "This two-drug regimen may provide an opportunity for people living with HIV to break the cycle of taking a daily pill and reduce their total treatment dosing days from 365 to six," Kimberly Smith, head of research and development, said.
- Barrons.com
The Drugs That Could Cure Coronavirus – and the Companies That Make Them
One analyst has some out-of-the box ideas about drugs already on the market from Gilead Sciences, AbbieVie, and GlaxoSmithKline.
- Reuters
Merck KGaA forecasts strong profit growth on healthcare, lab gear
Germany's Merck KGaA said adjusted core earnings would see "strong" growth, excluding the effect of currency swings, driven by its prescription drugs unit and the lab equipment business. The company said that while the impact of the current coronavirus epidemic was difficult to determine, it was currently working on the assumption that the outbreak would reach its high point in the first quarter and subside during the second.
- American City Business Journals
RTP company wants to know if Uber, Lyft could help fight HIV
Durham's Viiv Healthcare is launching a study in the Carolinas looking at how Uber and Lyft could improve patients outcomes in the Carolinas and usher in a new modality of care.
- Zacks
Trump Asks Pharma Firms to Step Up Coronavirus Vaccine Work
President Donald Trump asks pharmaceutical companies working on making vaccines or treatments for coronavirus to accelerate development.
- Reuters
Trump administration says drug makers will work together to combat coronavirus
The Trump administration said on Monday it had secured commitments from top pharmaceutical companies to work together to develop a vaccine and treatments to fight the coronavirus. At a meeting with industry executives at the White House, President Donald Trump exhorted the companies to collaborate to speed the process of getting a vaccine and therapeutics to victims of the virus. The White House, which has clashed previously with the pharmaceutical industry over high drug prices and has been struggling in recent weeks to show it is on top of the virus response, saw the meeting as a victory.
